Uni-Pixel (UNXL) Continues Higher Following Exclusive Film Deal; Hits New 52-Week High

Go back to Uni-Pixel (UNXL) Continues Higher Following Exclusive Film Deal; Hits New 52-Week High

Unusual 11 Mid-Day Movers 12/11: (BGMD) (SOMX) (ACUR) Higher; (PLG) (CBMX) (SPW) Lower

December 11, 2012 2:23 PM EST

BG Medicine, Inc. (Nasdaq: BGMD) 133.8% HIGHER; obtained a CE Mark enabling the commercial sale of the CardioSCORE test in the EU and other countries that recognize the CE Mark.

Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX) 76.2% HIGHER; Pernix Therapeutics Holdings, Inc. (AMEX: PTX) will acquire Somaxon for $25 million.

Acura Pharmaceuticals, Inc. (Nasdaq:... More

Notable 52-Week Highs and Lows of the Day 12/10: (NXY) (CLDX) (UNXL) High; (ZGNX) (CERP) (CSFS) Low

December 10, 2012 2:03 PM EST

This report is an intraday check of some of the more notable stocks that have hit a 52-week high or low so far today.

52-Week High:Nexen, Inc. (NYSE: NXY) $26.98. Candian regulators approved CNOOC's (NYSE: CEO) proposed acquisition of Nexen late last Friday. However CEO Kevin Reinhart... More

Unusual 11 Mid-Day Movers 12/10: (ACUR) (UNXL) (IVAN) Higher; (ZGNX) (CSFS) (HEB) Lower

December 10, 2012 1:02 PM EST

Zogenix, Inc. (Nasdaq: ZGNX) 46.8% LOWER; announced that the U.S. Food and Drug Administration's (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) voted 2-11 [with 1 abstention] against the approval of Zohydro ER (hydrocodone bitartrate extended-release capsules), an extended-release formulation of hydrocodone without acetaminophen, for the management of moderate-to-severe chronic pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.

Acura Pharmaceuticals, Inc. (Nasdaq: ACUR) 39.2% HIGHER; announced the launch of Nexafed?... More

Unusual 11 Mid-Day Movers 12/07: (CBMX) (UNXL) (JKS) Higher; (AMRN) (KUTV) (VTSS) Lower

December 7, 2012 12:59 PM EST

CombiMatrix (Nasdaq: CBMX) 194.9% HIGHER; announced that a pair of studies published in a leading journal favor chromosomal microarray analysis (CMA) over traditional karyotyping for genetic prenatal diagnosis and genetic evaluation of stillbirths.

Amarin Corporation plc (Nasdaq: AMRN) 18.9% LOWER; announced today a $100 million non-equity financing with an investment fund managed by Pharmakon Advisors and is hiring 250-300 specialty sales professionals for the launch of Vascepa for its initial indication, the MARINE... More